Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues:
Total revenues	$ 90	$ 22	$ 387	$ 76
Costs and expenses:
Production costs	399	272	887	830
Research and development	787	1,342	3,284	3,244
General and administrative	1,556	1,634	4,839	5,721
Total costs and expenses	2,742	3,248	9,010	9,795
Operating loss	(2,652)	(3,226)	(8,623)	(9,719)
Interest expense and other finance costs	(51)		(70)
Interest and other income/expense	13	40	60	156
Redeemable warrants valuation adjustment	1,438	103	2,361	103
Insurance proceeds from legal settlement, net		190		1,626
Gain (Loss) on sales of short term marketable securities		31	6	(56)
Gain from sale of income tax net operating losses and research credits				1,561
Net loss	(1,252)	(2,862)	(6,266)	(6,329)
Other comprehensive income (loss):
Reclassification adjustments for loss on sales of short term marketable securities included in net loss		(31)	(6)	56
Unrealized gain on marketable securities	11	15	40	112
Net comprehensive loss	$ (1,241)	$ (2,878)	$ (6,232)	$ (6,161)
Basic and diluted loss per share	$ (0.04)	$ (0.13)	$ (0.23)	$ (0.30)
Weighted average shares outstanding, basic and diluted	30,096,500	21,832,940	27,598,715	21,046,418
US [Member]
Revenues:
Clinical treatment programs	$ 4	$ 22	$ 101	$ 76
Europe [Member]
Revenues:
Clinical treatment programs	$ 86		$ 286